Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Flinn IW, et al. Among authors: kwan yl. Blood. 2014 May 8;123(19):2944-52. doi: 10.1182/blood-2013-11-531327. Epub 2014 Mar 3. Blood. 2014. PMID: 24591201 Free PMC article. Clinical Trial.
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.
Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP; Australasian Leukaemia and Lymphoma Group. Yeung DT, et al. Among authors: kwan yl. Blood. 2015 Feb 5;125(6):915-23. doi: 10.1182/blood-2014-07-590315. Epub 2014 Dec 17. Blood. 2015. PMID: 25519749 Free PMC article. Clinical Trial.
High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.
Nath CE, Trotman J, Tiley C, Presgrave P, Joshua D, Kerridge I, Kwan YL, Gurney H, McLachlan AJ, Earl JW, Nivison-Smith I, Zeng L, Shaw PJ. Nath CE, et al. Among authors: kwan yl. Br J Clin Pharmacol. 2016 Jul;82(1):149-59. doi: 10.1111/bcp.12906. Epub 2016 Apr 27. Br J Clin Pharmacol. 2016. PMID: 26879446 Free PMC article.
Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice.
Trotman J, Trinh J, Kwan YL, Estell JA, Fletcher J, Archer K, Lee K, Foo K, Curnow J, Bianchi A, Wignall L, Verner E, Gasiorowski R, Siedlecka E, Cunningham I. Trotman J, et al. Among authors: kwan yl. Intern Med J. 2017 May;47(5):542-548. doi: 10.1111/imj.13302. Intern Med J. 2017. PMID: 27753208
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.
Iland H, Bradstock K, Seymour J, Hertzberg M, Grigg A, Taylor K, Catalano J, Cannell P, Horvath N, Deveridge S, Browett P, Brighton T, Chong L, Springall F, Ayling J, Catalano A, Supple S, Collins M, Di Iulio J, Reynolds J; Australasian Leukaemia and Lymphoma Group. Iland H, et al. Haematologica. 2012 Feb;97(2):227-34. doi: 10.3324/haematol.2011.047506. Epub 2011 Oct 11. Haematologica. 2012. PMID: 21993673 Free PMC article. Clinical Trial.
41 results